Related Experiment Videos
Pneumonia due to resistant Streptococcus pneumoniae
1Institute for Infectious Diseases, University of Berne, and University Hospital Inselspital, Berne. martin.taeuber@imm.unibe.ch
Abstract:
In the past 10 to 20 years the pneumococcus, the most common pathogen of community-acquired pneumonia, has developed resistance to most antibiotics used for its treatment. Classes with important resistance problems include the beta-lactams, the macrolides and lincosamides, trimethoprim-sulfamethoxazole, and the tetracyclines. Unfortunately, resistance to more than one class of antibiotics is common in pneumococci, and their treatment is thus becoming more difficult. Patients likely to harbour resistant organisms include young children, particularly those attending day care, older patients, and subjects who have received recent antibiotic therapy, suffer from underlying diseases including HIV, or have nosocomial or polymicrobial pneumonia. The consequences of resistance development are different for different classes of antibiotics. With beta-lactams, the increase in minimal inhibitory concentrations is usually moderate in resistant strains, and because of the high concentrations that can be achieved with this class of drugs resistance does not usually lead to treatment failure. Thus, beta-lactams continue to be important drugs for the treatment of pneumococcal pneumonia, even if the organism is resistant. In contrast, resistance to other classes of antibiotics must be assumed to render these drugs ineffective. Newer quinolones represent valuable alternatives for the treatment of pneumococcal pneumonia, since their efficacy is not affected by resistance to other classes of antibiotics and they cover almost all pathogens of community-acquired pneumonia, including the atypical pathogens. However, they should be used with restraint in order to preserve this valuable class of drugs.
Insights
Pneumococcus is increasingly resistant to common antibiotics, complicating pneumonia treatment. Newer fluoroquinolones are effective alternatives but should be used judiciously to maintain their efficacy.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Background:
- The pneumococcus is a leading cause of community-acquired pneumonia.
- Antibiotic resistance in pneumococcus has significantly increased over the past 10-20 years.
- Resistance affects multiple antibiotic classes, including beta-lactams, macrolides, lincosamides, trimethoprim-sulfamethoxazole, and tetracyclines.
Purpose of the Study:
- To review the impact of antibiotic resistance on the treatment of pneumococcal pneumonia.
- To identify patient groups at higher risk for resistant pneumococcal infections.
- To evaluate the efficacy of different antibiotic classes against resistant pneumococcus.
Main Methods:
- Literature review of antibiotic resistance trends in Streptococcus pneumoniae.
- Analysis of treatment outcomes for community-acquired pneumonia caused by resistant strains.
- Evaluation of antibiotic class effectiveness based on resistance profiles.
Main Results:
- Pneumococcus exhibits widespread resistance to common antibiotic classes.
- Multidrug resistance is prevalent, making treatment challenging.
- Beta-lactams remain viable for resistant strains due to achievable concentrations, though resistance necessitates careful consideration.
- Resistance to macrolides, lincosamides, trimethoprim-sulfamethoxazole, and tetracyclines often renders these drugs ineffective.
- Newer fluoroquinolones are effective against resistant pneumococci and atypical pathogens.
Conclusions:
- Antibiotic resistance significantly complicates pneumococcal pneumonia management.
- Risk factors for resistant infections include young children, elderly patients, recent antibiotic use, and underlying conditions.
- Beta-lactams retain utility, but newer fluoroquinolones offer a crucial alternative, necessitating judicious use to preserve their effectiveness.